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Abstract
Background: Surgical resection has remained the mainstay of treatment of GIST with a 5-year-
survival of 28–35%. Tyrosine kinase inhibitor (Imatinib) has revolutionised the treatment of these
tumours. The current research is directed towards expanding the role of this drug in the treatment
of GIST. We present our experience of managing GIST in this institute.
Methods: This is a case note study of patients identified from a prospectively kept database from
January 2000 to August 2007.
Results: 16 patients were diagnosed with GIST. The median age was 66 years (range 46 to 82) and
the male to female ratio was 9:7. Eleven patients underwent surgery, 9 of which had R0 resection
(2 laparoscopic, 1 converted to open), one had an open biopsy and one had a debulking procedure.
3 patients were inoperable and 2 were found to be unfit for surgery. Five patients received Imatinib
(2 postoperatively). The risk assessment based on morphological criteria showed that 4 patients
had low, 4 had intermediate and 8 had high malignant potential. The median follow up was for 12
months (range 3–72); 2 patients died of unrelated causes at 6 and 9 months after diagnosis.
Conclusion: Most GISTs can be managed effectively using existing protocols. However currently
there is no evidence based guidance available on the management of GIST in the following
situations-role of debulking surgery, the follow up of benign tumours not requiring surgical
resection and role of laparoscopic surgery. Further research is needed to answer these questions.
Background
Gastrointestinal stromal tumours (GIST) represent a sub-
group of mesenchymal tumours, which were traditionally
known as leiomyomas or leiomyosarcomas and have tra-
ditionally been treated by surgery. The results of a simple
surgical resection with clear margins were comparable to
those of a radical resection [1]. Therefore until recently
simple resectional surgery remained the mainstay of treat-
ment with 5-year-survival rates of 28–35%[2,3] for R0
resections. Introduction of Imatinib mesylate (tyrosine
kinase inhibitor) for the treatment of GIST at the begin-
ning of this century has improved outcomes in metastatic
and unresectable tumours. Demetri et al have shown that
Imatinib is useful in the treatment of unresectable or met-
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astatic GIST with more than half the patients showing a
sustained response [4]. Verweij et al have shown that a
dose of 400 mg twice a day achieves significantly longer
progression-free survival [5]. Two small retrospective
studies have suggested that neoadjuvant Imatinib therapy
may have a role in advanced GIST and have suggested a
prospective evaluation [6,7]. Most of the current research
is directed towards establishing the role of Imatinib as an
adjuvant to surgery [8-11]. Management of small GIST is
mainly in the form of watchful waiting as suggested in the
consensus statement by ESMO[12], however there is no
strong evidence to support this statement.
In spite of these developments the role of surgery itself has
remained unchanged. We present our experience of 16
cases managed in this institute since introduction of Imat-
inib.
Methods
A case note study of all the patients diagnosed with GIST
from January 2000 to August 2007 was carried out. Cases
were identified from a prospectively kept database in the
unit.
Results
16 patients were diagnosed with GIST during the study
period. The demographics, presentation, histology, man-
agement and follow up of these patients are summarised
in Table 1. Eleven patients underwent surgery, 9 of which
had R0 resection. Two of these patients had laparoscopic
wedge excision and in one laparoscopic operation had to
be converted to open to ensure R0 resection. One patient
had an open biopsy to confirm the diagnosis before com-
mencing Imatinib. The median follow up was for 12
months (range 3–72). Two patients died of unrelated
causes at 6 and 9 months after the diagnosis.
Patient 6 was operated by Gynaecologist for fibroids and
intraoperatively surgeons were called to remove a large
irregular mass adherent to the greater curvature of the
stomach and infiltrating the omentum. There was no evi-
dence of peritoneal or liver metastasis. The mass was
removed completely which proved to be GIST on histol-
ogy with possible extra-gastrointestinal or gastric in ori-
gin.
Patients 9 and 13 had GIST in the oesophagus and the sec-
ond part of the duodenum respectively. Due to their asso-
Table 1: Summary of patients with GIST
Patient Age, 
Gender







Operation Imatinib Follow up 
(months)
Risk
1 66, F Stomach Mass 70 Positive 10/50 Wedge 
resection
No 5, SD High
2 82, M stomach GI bleed 60 Positive 2/50 Wedge 
resection
No 12, SD Inter
3 60, M Stomach GI bleed 75 Positive 2/50 Lap to open 
Wedge 
resection
No 12, SD Inter
4 72, M Stomach Pain and 
distension
110 Positive 300/50 Debulking Yes 22, SD High
5 51, M Stomach Mass 14.5 Positive None seen Inoperable* Yes 3, PD High




260 Positive 8/50 Excision and 
total 
hysterectomy
Yes # 45, SD High
7 72, M Stomach Mass 90 Positive 17/50 Inoperable** Yes 6, Died of MI High
8 68, F Stomach GI bleed 70 Positive 4/50 Lap. wedge 
resection
No 24, SD Inter
9 70, F Oesophagus Dysphagia 20 N/A N/A Not fit No 29, SD N/A
10 46, F Stomach GI bleed 70 Positive 10/50 Distal 
gastrectomy
No 3 < SD High
11 77, F Stomach GI bleed 80 Positive 34/50 Distal 
gastrectomy
No 9, Died High
12 47, M Stomach GI bleed 50 Not done Not done Wedge 
resection
No 72, SD N/A
13 60, M Duodenum Incidental 13 N/A N/A Not fit No 14, SD N/A
14 74, F Stomach GI bleed 40 Positive 2/50 Lap. wedge 
resection
No 9, SD Low
15 57, M Duodenum Cholangitis 40 Positive 
Negative
None Duodenectomy No 62, SD Low
16 76, M Stomach GI bleed 65 Negative 2/50 No Yes 7, SD Inter
N/A: No histological diagnosis available
*: Metastatic disease
**: locally advanced
#: Imatinib was commenced 2 years after the operation when patient was found to have recurrence.
SD: static disease at last follow up.
PD: progressive disease at last follow up.World Journal of Surgical Oncology 2008, 6:77 http://www.wjso.com/content/6/1/77
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ciated co-morbidities they were deemed unfit for major
resectional surgery. In both the cases endoscopic biopsies
were insufficient to give the histological diagnosis, but
EUS (endoscopic ultrasound) findings were consistent
with the diagnosis of GIST. They were both followed up
by yearly EUS examinations.
Patient 16 had significant iscaemic heart disease and
could not withstand staging laparoscopy and hence the
operation is deferred till cardiac status improves.
Discussion
This cohort of patients showed a significant variation in
presentation and wide range of disease stages at presenta-
tion. Most of these patients could be managed effectively
with surgery and/or Imatinib using current protocols.
Imatinib was used in patients with unresectable or meta-
static disease according to the NICE guidelines[13].
Our experience suggests that current guidelines are clear
for the management of unresectable and metastatic GIST;
however surgeons are faced with management dilemmas
in the following situations.
• Small GIST
Small GISTs are often diagnosed radiologically as an inci-
dental finding (patient 13 in our series). They are labelled
as "benign" purely on the basis of their size and radiolog-
ical appearance. These tumours, particularly those located
in the oesophagus or the duodenum, are difficult to
biopsy and in the absence of histological diagnosis there
is a potential risk of keeping a malignant GIST under
observation or exposing benign GIST to unnecessary sur-
gery. This unnecessary surgery could mean a pancreati-
coduodenectomy in such a patient or an oesophagectomy
in patient 9, if deemed fit for operation. Currently there is
no guidance available on the rationale of regular follow
up or of the use of Imatinib in these patients. There are
few reported series of endoscopic enucleation of these
tumours [14,15]. However this is not a widely accepted
practice due to lack of robust evidence.
Many patients with a small GIST and requiring regular fol-
low up do not get reported leading to a lack of data regard-
ing long-term survival. There is a need for a central
database of these cases to improve reporting and long-
term follow-up.
• Debulking surgery
At the other end of the spectrum are locally advanced
tumours (such as patient 4 in our series). This patient
clearly benefited from "debulking" surgery followed by
Imatinib. He underwent debulking surgery due to pres-
sure symptoms even in the presence of peritoneal metas-
tasis. This approach, which would have been seen as
"unconventional" then, proved to be beneficial to the
patient. This supports the current view of using Imatinib
with cytoreductive surgery for synchronous metastasis
[16]. Currently there are number of reports showing
increased recurrence-free and overall survival after surgery
for metastatic GIST following TKI therapy [17-19]. How-
ever, these reports were largely comprised of patients with
recurrent disease after the initial resection of the primary
disease, and none specifically focused on the role of pri-
mary debulking surgery.
The role of surgery may need redefining in such patients.
• Adjuvant therapy with Imatinib
There are reports showing benefits of adjuvant Imatinib in
GIST of high malignant potential [9]. Current trials (ACO-
SOG Z9000, ACOSOG Z9001, EORTC and SSG XVIII) are
addressing the role of adjuvant Imatinib in different
groups of patients. The interim results of ACOSOG Z9001
suggest that Imatinib increases recurrence-free survival
when administered following the complete resection of a
primary GIST. Our number-6 patient could have poten-
tially benefited from such therapy. She had an excision of
a large tumour found incidentally by the gynaecologists.
This proved to be GIST of high malignant potential on
histology. Adjuvant treatment was not administered, as
she had an R0 resection. She remained disease free for 2
years but subsequently developed peritoneal metastasis,
which were then treated with Imatinib. We believe that
the treatment of such patients should be more aggressive
with the use of adjuvant Imatinib while waiting for the
final outcomes of ongoing trials.
• Laparoscopic surgery
The change in nomenclature from leiomyosarcoma to
GIST and the advent of Imatinib has changed the general
perception of these tumours to be of benign nature, and
there is an increasing trend towards laparoscopic treat-
ment [20,21]. It is evident from current literature that R0
resections give the best chance of long term cure to such
patients and that tumour spillage along with an R1/R2
resection is associated with an increased incidence of
recurrence [22]. We feel that GIST should be treated fol-
lowing the principles of "cancer surgery" and that open
resection with adequate margins should be performed
unless an R0 resection is achievable laparoscopically.
Due to limited number of patients we have not applied
any statistics to the data but tried to highlight the grey
areas in the management of these patients.
Conclusion
We feel that future surgical trials need to be directed
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￿ Long-term follow up of small GIST located in areas that
are not readily accesible and diagnosed soley on radiologi-
cal findings and are presumed to be benign.
￿ Defining the role of debulking surgery, with or without
down staging of disease.
Laparoscopic surgery should be considered only if it is not
compromising the principles of cancer surgery.
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